Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Schiff, R"'
Autor:
Schettini F; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain., Pascual T; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Conte B; Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genova, Italy., Chic N; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Galván P; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain., Martínez O; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Adamo B; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Vidal M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Muñoz M; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Fernández-Martinez A; Department of Genetics, University of North Carolina, Chapel Hill, USA., Rognoni C; Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Milan, Italy., Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto - IRCCSS, Padova, Italy., Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto - IRCCSS, Padova, Italy., Conte PF; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy; Division of Medical Oncology 2, Istituto Oncologico Veneto - IRCCSS, Padova, Italy., Locci M; Department of Neuroscience, Reproductive Medicine, Odontostomatology, University of Naples Federico II, Naples, Italy., Brase JC; Novartis Pharma AG, Basel, Switzerland., Gonzalez-Farre B; Department of Pathology, Hospital Clinic, Barcelona, Spain., Villagrasa P; SOLTI Breast Cancer Research Group, Barcelona, Spain., De Placido S; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Schiff R; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Veeraraghavan J; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Rimawi MF; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Osborne CK; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Pernas S; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Institut Català d'Oncologia-H. U. Bellvitge-IDIBELL, Barcelona, Spain., Perou CM; Department of Genetics, University of North Carolina, Chapel Hill, USA., Carey LA; Department of Medicine, University of North Carolina, Chapel Hill, USA., Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. Electronic address: alprat@clinic.cat.
Publikováno v:
Cancer treatment reviews [Cancer Treat Rev] 2020 Mar; Vol. 84, pp. 101965. Date of Electronic Publication: 2020 Jan 17.
Autor:
Prat A; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain., Pascual T; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain., De Angelis C; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX., Gutierrez C; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX., Llombart-Cussac A; Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain., Wang T; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Cortés J; IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Rexer B; Department of Medicine, Vanderbilt University, Nashville, TN., Paré L; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain., Forero A; Department of Medicine, University of Alabama-Birmingham, Birmingham, AL., Wolff AC; Johns Hopkins University, Baltimore, MD., Morales S; Department of Medical Oncology, Hospital Universitari Arnau Vilanova, Lleida, Spain., Adamo B; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Brasó-Maristany F; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Vidal M; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Veeraraghavan J; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX., Krop I; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA., Galván P; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Pavlick AC; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Bermejo B; Department of Medical Oncology, Hospital Clínico de Valencia, Valencia, Spain., Izquierdo M; Novartis Oncology, Basel, Switzerland., Rodrik-Outmezguine V; Novartis Oncology, Basel, Switzerland., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Hilsenbeck SG; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX., Oliveira M; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Dieci MV; Department of Genetics, University of North Carolina, Chapel Hill, NC.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Griguolo G; Department of Genetics, University of North Carolina, Chapel Hill, NC.; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., Fasani R; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Nuciforo P; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Parker JS; Department of Genetics, University of North Carolina, Chapel Hill, NC., Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy., Schiff R; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX., Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy., Osborne CK; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX., Rimawi MF; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.; Department of Medicine, Baylor College of Medicine, Houston, TX.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2020 Jan 01; Vol. 112 (1), pp. 46-54.
Autor:
Chung A; Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: alice.chung@cshs.org., Choi M; Cedars-Sinai Medical Center, Los Angeles, CA., Han BC; Cedars-Sinai Medical Center, Los Angeles, CA., Bose S; Cedars-Sinai Medical Center, Los Angeles, CA., Zhang X; Cedars-Sinai Medical Center, Los Angeles, CA., Medina-Kauwe L; Cedars-Sinai Medical Center, Los Angeles, CA., Sims J; Cedars-Sinai Medical Center, Los Angeles, CA., Murali R; Cedars-Sinai Medical Center, Los Angeles, CA., Taguiam M; Cedars-Sinai Medical Center, Los Angeles, CA., Varda M; Cedars-Sinai Medical Center, Los Angeles, CA., Schiff R; Baylor College of Medicine, Houston, TX., Giuliano A; Cedars-Sinai Medical Center, Los Angeles, CA., Cui X; Cedars-Sinai Medical Center, Los Angeles, CA.
Publikováno v:
Clinical breast cancer [Clin Breast Cancer] 2015 Dec; Vol. 15 (6), pp. 448-457.e2. Date of Electronic Publication: 2015 Jun 19.
Autor:
Putluri N; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA., Maity S; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA., Kommagani R; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA., Creighton CJ; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Putluri V; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA., Chen F; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Nanda S; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Bhowmik SK; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA., Terunuma A; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dorsey T; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Nardone A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Fu X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Shaw C; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Sarkar TR; Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schiff R; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Lydon JP; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA., O'Malley BW; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Ambs S; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Das GM; Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA., Michailidis G; Department of Statistics, University of Michigan, Ann Arbor, MI, USA. Electronic address: gmichail@umich.edu., Sreekumar A; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA; Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA; Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: arun.sreekumar@bcm.edu.
Publikováno v:
Neoplasia (New York, N.Y.) [Neoplasia] 2014 May; Vol. 16 (5), pp. 390-402.
Autor:
Healy NA; Discipline of Surgery, National University of Ireland, Galway, Republic of Ireland. nuala.healy@nuigalway.ie, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ
Publikováno v:
International journal of cancer [Int J Cancer] 2012 Nov 15; Vol. 131 (10), pp. 2215-22. Date of Electronic Publication: 2012 Jul 30.
Autor:
Creighton CJ; Dan L Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030, USA. creighto@bcm.edu, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2009 Mar; Vol. 114 (2), pp. 287-99. Date of Electronic Publication: 2008 Apr 19.
Autor:
Arpino G; Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA., Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2005 Sep 07; Vol. 97 (17), pp. 1254-61.
Autor:
Osborne CK; Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. kosborne@breastcenter.tmc.edu, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2003 Mar 05; Vol. 95 (5), pp. 353-61.
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat
Publikováno v:
Cancer Treat Rev
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456360a8625da925d93580bf31f87b0f
https://europepmc.org/articles/PMC7230134/
https://europepmc.org/articles/PMC7230134/